Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 26, 2022 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)

- 141 MDS Patients Enrolled -- Topline Data Anticipated 1H:2023 - SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for...
February 28, 2022 16:01 ET | Source: FibroGen, Inc.

FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results

Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
February 14, 2022 07:00 ET | Source: FibroGen, Inc.

FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results

SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close....
October 26, 2021 07:00 ET | Source: FibroGen, Inc.

FibroGen to Report Third Quarter 2021 Financial Results

SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will...
October 25, 2021 07:00 ET | Source: FibroGen, Inc.

FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021

SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American...
April 28, 2021 07:00 ET | Source: FibroGen, Inc

FibroGen to Present at Upcoming Investor Conference

SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities...
May 27, 2020 07:00 ET | Source: FibroGen, Inc

FibroGen to Present at Upcoming Investor Conferences

SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
December 02, 2019 07:00 ET | Source: FibroGen, Inc

FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s...
November 08, 2019 14:10 ET | Source: FibroGen, Inc

FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+ Roxadustat did not increase risk...